Achilles Therapeutics Income Statement

Financials in millions ZAR. Fiscal year is April - March.

Millions ZAR. Fiscal year is Apr - Mar.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '25 Mar 2, 2025	Feb '24 Feb 25, 2024	Feb '23 Feb 26, 2023	Feb '22 Feb 27, 2022
Revenue	42,344	37,419	31,897	26,583
Revenue Growth (YoY)	13.16%	17.31%	19.99%	-
Cost of Revenue	33,291	29,498	25,164	21,421
Gross Profit	9,053	7,921	6,733	5,162
Selling, General & Admin	7,057	6,089	5,366	4,384
Other Operating Expenses	-312	-269	-247	-204
Operating Expenses	6,745	5,820	5,119	4,180
Operating Income	2,308	2,101	1,614	982
Interest Expense	-458	-342	-295	-275
Interest & Investment Income	91	91	54	46
EBT Excluding Unusual Items	1,941	1,850	1,373	753
Gain (Loss) on Sale of Assets	-29	-16	-6	131
Asset Writedown	-4	-11	-6	-129
Pretax Income	1,908	1,823	1,531	1,156
Income Tax Expense	525	438	427	302
Net Income	1,383	1,385	1,104	854
Net Income to Common	1,383	1,385	1,104	854
Net Income Growth	-0.14%	25.45%	29.27%	-
Shares Outstanding (Basic)	340	300	34	34
Shares Outstanding (Diluted)	341	300	34	34
Shares Change (YoY)	13.69%	779.12%	-	-
EPS (Basic)	4.07	4.62	32.35	25.03
EPS (Diluted)	4.06	4.62	32.35	25.03
EPS Growth	-12.16%	-85.73%	29.27%	-
Free Cash Flow	1,504	1,793	998	885
Free Cash Flow Per Share	4.41	5.98	29.25	25.93
Dividend Per Share	-	14.652	8.495	63.349
Dividend Growth	-	72.47%	-86.59%	-
Gross Margin	21.38%	21.17%	21.11%	19.42%
Operating Margin	5.45%	5.62%	5.06%	3.69%
Profit Margin	3.27%	3.70%	3.46%	3.21%
Free Cash Flow Margin	3.55%	4.79%	3.13%	3.33%
EBITDA	2,913	2,635	2,070	1,337
EBITDA Margin	6.88%	7.04%	6.49%	5.03%
D&A For EBITDA	605	534	456	355
EBIT	2,308	2,101	1,614	982
EBIT Margin	5.45%	5.62%	5.06%	3.69%
Effective Tax Rate	27.52%	24.03%	27.89%	26.13%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.